Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEPHALOTHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEPHALOTHIN.
CEFTAROLINE FOSAMIL vs CEPHALOTHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking peptidoglycan cross-linking. It has activity against gram-positive cocci (e.g., Staphylococcus aureus, Streptococcus pyogenes) and some gram-negative bacilli (e.g., Escherichia coli, Klebsiella pneumoniae).
600 mg IV every 12 hours infused over 1 hour
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
0.5-1 hour in patients with normal renal function; prolonged to 2-8 hours in moderate renal impairment (CrCl 30-50 mL/min); up to 20-30 hours in end-stage renal disease; due to rapid elimination, frequent dosing (q4-6h) is required for continuous bactericidal levels.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Primarily renal (60-90% unchanged) via tubular secretion and glomerular filtration; minor biliary excretion (less than 5%); hepatic metabolism to desacetylcephalothin (active but less potent) accounts for about 20-30% of dose; fecal elimination negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic